Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Neurology

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease

  • Guillaume Grolez2, 3,
  • Caroline Moreau2, 3,
  • Bernard Sablonnière4,
  • Guillaume Garçon5,
  • Jean-Christophe Devedjian1, 3,
  • Sayah Meguig1,
  • Patrick Gelé6,
  • Christine Delmaire3, 7,
  • Regis Bordet1, 3,
  • Luc Defebvre2, 3,
  • Ioav Z Cabantchik8 and
  • David Devos1, 2, 3, 5Email author
BMC Neurology201515:74

https://doi.org/10.1186/s12883-015-0331-3

Received: 19 November 2014

Accepted: 24 April 2015

Published: 6 May 2015

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
19 Nov 2014 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
24 Apr 2015 Editorially accepted
6 May 2015 Article published 10.1186/s12883-015-0331-3

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Medical Pharmacology, Lille Nord de France University
(2)
Department of Movement Disorders and Neurology, Lille Nord de France University
(3)
INSERM U1171, Lille Faculty of Medicine, Lille Nord de France University
(4)
Department of Molecular Biology and Pathology Centre, Unit 837, Team 1, INSERM Lille Faculty of Medicine, Lille University Hospital, Lille Nord de France University
(5)
Department of Toxicology, Public Health and Environment, EA 4483, Faculty of Pharmaceutic and Biological Sciences, Lille Nord de France University
(6)
Biological Resources Centre, Lille University Hospital
(7)
Department of Neuroradiology, Lille University Hospital
(8)
Della Pergola Chair, Alexander Silberman Institute of Life Sciences, Hebrew University

Advertisement